Inflammation: The protein C pathway

被引:8
作者
Esmon, CT
Fukudome, K
Mather, T
Bode, W
Esmon, NL
Regan, LM
StearnsKurosawa, DJ
Kurosawa, S
机构
[1] UNIV OKLAHOMA,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104
[2] UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73104
[3] HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104
[4] MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY
来源
FIBRINOLYSIS & PROTEOLYSIS | 1997年 / 11卷
关键词
ESCHERICHIA-COLI; THROMBIN; ACTIVATION; THROMBOMODULIN; SPECIFICITY; IDENTIFICATION; CONCENTRATE; DEFICIENCY; RECEPTOR; CLONING;
D O I
10.1016/S0268-9499(97)80041-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The protein C pathway serves as one of the most important negative regulatory mechanisms in coagulation. Unlike most pathways in coagulation, the protein C pathway can be downregulated by inflammatory mediators at the levels of protein C activation and function. Antiphospholipid antibodies can selectively block protein C function. In gram negative sepsis, protein C in humans and activated protein C (APC) in baboons and rodents have been shown to block the lethal response, at least in part by blocking the DIC response and probably by modulating the cytokine cascade. The mechanisms by which the pathway modulates inflammation remains unclear, but a novel endothelial cell specific receptor has recently been identified that binds APC and modulates enzyme specificity. Like thrombomodulin, the receptor is downregulated by the inflammatory cytokine, TNF. These observations provide a basis for a model in which the protein C pathway serves as a major regulatory mechanism in the control of coagulation and inflammation.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 25 条
  • [1] RECOGNITION OF A LIPID ANTIGEN BY CD1-RESTRICTED ALPHA-BETA(+) T-CELLS
    BEEKMAN, EM
    PORCELLI, SA
    MORITA, CT
    BEHAR, SM
    FURLONG, ST
    BRENNER, MB
    [J]. NATURE, 1994, 372 (6507) : 691 - 694
  • [2] Calabi F., 1991, Immunogenetics of the major histocompatibility complex., P215
  • [3] ACTIVATION OF PROTEIN-C INVIVO
    COMP, PC
    JACOCKS, RM
    FERRELL, GL
    ESMON, CT
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1982, 70 (01) : 127 - 134
  • [4] CONARD J, 1993, BLOOD, V82, P1159
  • [5] TREATMENT OF HOMOZYGOUS PROTEIN-C DEFICIENCY AND NEONATAL PURPURA FULMINANS WITH A PURIFIED PROTEIN-C CONCENTRATE
    DREYFUS, M
    MAGNY, JF
    BRIDEY, F
    SCHWARZ, HP
    PLANCHE, C
    DEHAN, M
    TCHERNIA, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (22) : 1565 - 1568
  • [6] AN UPDATE ON CLINICAL AND BASIC ASPECTS OF THE PROTEIN-C ANTICOAGULANT PATHWAY
    ESMON, CT
    SCHWARZ, HP
    [J]. TRENDS IN CARDIOVASCULAR MEDICINE, 1995, 5 (04) : 141 - 148
  • [7] IDENTIFICATION OF AN ENDOTHELIAL-CELL COFACTOR FOR THROMBIN-CATALYZED ACTIVATION OF PROTEIN-C
    ESMON, CT
    OWEN, WG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (04): : 2249 - 2252
  • [8] THROMBOMODULIN AS A MODEL OF MOLECULAR MECHANISMS THAT MODULATE PROTEASE SPECIFICITY AND FUNCTION AT THE VESSEL SURFACE
    ESMON, CT
    [J]. FASEB JOURNAL, 1995, 9 (10) : 946 - 955
  • [9] Espana F, 1996, THROMB HAEMOSTASIS, V75, P56
  • [10] MOLECULAR-CLONING AND EXPRESSION OF MURINE AND BOVINE ENDOTHELIAL-CELL PROTEIN C/ACTIVATED PROTEIN-C RECEPTOR (EPCR) - THE STRUCTURAL AND FUNCTIONAL CONSERVATION IN HUMAN, BOVINE, AND MURINE EPCR
    FUKUDOME, K
    ESMON, CT
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (10) : 5571 - 5577